title: [Reirradiation for recurrent or second primary head and neck cancers].
abstract: Recurrences or second primary head and neck cancers meant, for a long time, therapeutic dead ends. Surgery was the standard treatment, but could only be achieved in 25% of the patients. The GETTEC-GORTEC (99-01) randomized trial showed that radiochemotherapy improved disease-free survival for a highly selected population. For inoperable patients, three options can be discussed: supportive care only, chemotherapy or radiotherapy with or without chemotherapy. The EXTREME protocol showed that combining platinum, 5FU and cetuximab improved overall survival for recurrent or metastatic forms. This is certainly the best option for advanced forms, which are not accessible to radiotherapy. Concerning radiotherapy, only one randomized trial compared chemoradiotherapy to chemotherapy alone using methotrexate. The overall survival, the main objective in this study, was not improved, however, the enrollment was incomplete and included many advanced stage tumors. Other articles are based on Vokes' initial work of radiochemotherapy delivered in split-course over a period of 11 weeks. All conventional and conformational radiotherapy series showed improved local control and disease-free survival rates, but at the expense of acute and late toxicities demanding a drastic patients selection. New radiotherapy techniques such as intensity modulated radiotherapy (IMRT) and stereotactic body radiotherapy (SBRT) have reduced toxicities with a likely oncological results improvement, offering treatments which are spread over six to seven weeks for IMRT and two weeks for SBRT. The better treatment tolerance allows an increasing number of eligible patients. The main future objective will be to define the specific IMRT and SBRT indications.
authors.affiliation: Université Lille-II, centre Oscar-Lambret, service de radiothérapie, Lille, France.
authors.forename: Raphaëlle
authors.initials: R
authors.lastname: Mouttet-Audouard
authors.forename: Louis
authors.initials: L
authors.lastname: Gras
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Comet
authors.forename: Eric
authors.initials: E
authors.lastname: Lartigau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D059248:Chemoradiotherapy / Q000379:methods; D006258:Head and Neck Neoplasms / Q000532:radiotherapy* / Q000628:therapy; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000532:radiotherapy; D009364:Neoplasm Recurrence, Local / Q000532:radiotherapy* / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000532:radiotherapy* / Q000628:therapy; D016634:Radiosurgery / Q000379:methods; D020266:Radiotherapy, Conformal / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D019233:Retreatment; D016879:Salvage Therapy / Q000379:methods